Overview

Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this phase II study is to determine the efficacy of fenretinide in the treatment of geographic atrophy (GA) in subjects with the dry form of age-related macular degeneration (AMD).
Phase:
Phase 2
Details
Lead Sponsor:
Sirion Therapeutics, Inc.
Collaborator:
ReVision Therapeutics, Inc.
Treatments:
Fenretinide